MedTrace Logo

Local Therapy in Advanced NSCLC With Non-progressive Disease (PD) After First Line Therapy

NCT03046316 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-07-23

No results posted yet for this study

Summary

This is a prospective single arme real-world study clinical study, which aims to investigate the overall benefit and safety of consolidative therapy in advanced NSCLC (stage III/IV) patients , who do not progress after front line systemic therapy (chemotherapy, target therapy or immunological checkpoint inhibitors).

Conditions

  • Lung Neoplasms

Interventions

OTHER

local consolidative treatment

local consolidative treatment to primary or metastases, which includes surgery, radiotherapy or interventional therapy

Sponsors & Collaborators

  • Guangdong Association of Clinical Trials

    lead OTHER

Principal Investigators

  • Zhen Wang, PhD,MD · Guangdong General Hospital&Guangdong Academy of Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2022-07-01
Completion
2026-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03046316 on ClinicalTrials.gov